Trials / Recruiting
RecruitingNCT06990399
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
A Randomized, Double-masked, Sham-controlled, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal Tabirafusp Alfa (KSI-101) in Participants With Macular Edema Secondary to Inflammation (MESI) - PEAK
- Status
- Recruiting
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- Sponsor
- Kodiak Sciences Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A Phase 3 Study to Evaluate the Efficacy and Safety of Intravitreal KSI-101 in Participants with Macular Edema Secondary to Inflammation (MESI)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | KSI-101 | Intravitreal injection |
| OTHER | Sham Comparator | Sham injections |
Timeline
- Start date
- 2025-07-30
- Primary completion
- 2026-02-01
- Completion
- 2027-07-01
- First posted
- 2025-05-25
- Last updated
- 2025-09-10
Locations
33 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06990399. Inclusion in this directory is not an endorsement.